320 related articles for article (PubMed ID: 21506905)
1. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Burris HA
Expert Opin Biol Ther; 2011 Jun; 11(6):807-19. PubMed ID: 21506905
[TBL] [Abstract][Full Text] [Related]
2. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].
Gonçalves A; Trédan O; Villanueva C; Dumontet C
Bull Cancer; 2012 Dec; 99(12):1183-91. PubMed ID: 23247898
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Van den Mooter T; Teuwen LA; Rutten A; Dirix L
Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab emtansine in breast cancer.
Dirix LY; Rutten A; Huget P; Dirix M
Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX
Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071
[TBL] [Abstract][Full Text] [Related]
9. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody.
Burris HA
Am Soc Clin Oncol Educ Book; 2012; ():159-61. PubMed ID: 24451727
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
13. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
[TBL] [Abstract][Full Text] [Related]
15. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
Lambert JM; Chari RV
J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
[TBL] [Abstract][Full Text] [Related]
16. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
[TBL] [Abstract][Full Text] [Related]
18. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
Lu D; Burris HA; Wang B; Dees EC; Cortes J; Joshi A; Gupta M; Yi JH; Chu YW; Shih T; Fang L; Girish S
Curr Drug Metab; 2012 Sep; 13(7):911-22. PubMed ID: 22475266
[TBL] [Abstract][Full Text] [Related]
19. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.
Sadeghi S; Olevsky O; Hurvitz SA
Pharmgenomics Pers Med; 2014; 7():329-38. PubMed ID: 25378946
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
Doroshow DB; LoRusso PM
Future Oncol; 2018 Mar; 14(7):589-602. PubMed ID: 29214842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]